Adaptimmune

Leading The Cancer Revolution

Adaptimmune Therapeutics
60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom

adaptimmune.com

Investor Relations
Juli P. Miller, Ph.D.
VP, Corporate Affairs
& Investor Relations
M: +1-215-460-8920
Juli.Miller@adaptimmune.com

NASDAQ
ADAP

Share Price[1]	$0.44
Market Cap[1]	$107.4M
Shares Outstanding	227.1M
Float	196.9M
Cash & Cash Equivalents[2]	$90.1M

1) As of December 21,2023
2) At September 30,2023

Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.

Investment Highlights

- **The leader in cell therapies for solid tumors**
  Solid tumors represent ~90% of all cancers
- **Deep clinical late-stage pipeline**
  Paths to products targeting MAGE-A4 and NY-ESO
- **Multiple near-term catalysts**
  Clinical development decisions driven by data
- **End-to-end capabilities**
  Experienced teams successfully advancing and manufacturing T-cell therapies
- **Cash runway into 2026**
  Strong balance sheet to finance multiple catalysts

Mission & Vision

To transform the lives of people with cancer by designing, developing, and delivering cell therapies.

Arming cells.
Against cancer.
For good.

Cell & Gene Therapies Set to Transform the Treatment Landscape

Monoclonal Antibodies (mAbs)



Cell & Gene Therapies*



mAbs drove most M&A since 1997
Total: **>$187B**

Centocor · BASF · IDEC · Biogen · Schering-Plough · MedImmune · Genentech · Wyeth

M&A of CGT since 2017 already **> $25B**

Kite · Spark · JUNO · TMUNITY

*includes combination ATMPs - advanced therapy medicinal products
^possible launch dates dependent on FDA approval
Source: Evaluate Pharma – Consensus Forecast Sales, accessed Dec.15, 2022; additional reference

Wholly Owned Pipeline with Late-Stage Assets for Solid Tumors

PROGRAM [TARGET]	TRIAL NAME(S)/ INDICATION(S)/DESIGN	IND-ENABLING	PHASE 1	PHASE 2/3	REGISTRATION
afami-cel [MAGE-A4]	SPEARHEAD-1 pivotal trial Synovial Sarcoma				
lete-cel [NY-ESO]	IGNYTE-ESO Synovial sarcoma and MRCLS				
ADP-A2M4CD8* [MAGE-A4]	SURPASS-3 registration-directed trial Platinum resistant or refractory ovarian cancer; Monotherapy; +/- checkpoint inhibitor				
	SURPASS Ph1 Head & neck cancer Focus on earlier line therapy +/- checkpoint inhibitor				
	SURPASS Ph1 urothelial cancer Focus on earlier line therapy +/- checkpoint inhibitor				
ADP-600 [PRAME]	Indications that express PRAME including synovial sarcoma, breast, NSCLC, kidney, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers Clinical Indications TBD				
ADP-520 [CD70]	Indications that express CD70 including hematological malignancies: acute myeloid leukemia (AML), lymphoma and renal cell carcinoma (RCC) Clinical Indications TBD				

Sarcoma franchise

*SURPASS Ph 1 no longer enrolling for indications other than head & neck and urothelial cancers

Sarcoma Franchise

Afami-cel

Advanced autologous engineered TCR program targeting MAGE-A4

Validated target with annual mortality of >82,000[1] patients (US and EU) with MAGE-A4+ tumors

- Clinically validated “clean” target; member of cancer testis antigen family
- Expression across broad range of solid tumors confirmed by screening protocol
- In early- and late-phase clinical trials with acceptable safety profile, to date, and responses in multiple solid tumor indications
- Expression levels ranging from ~15% to ~70%[2] across tumors
- Encouraging responses in:
  - Synovial sarcoma afami-cel
  - Ovarian
  - Head & neck
  - Bladder
  - Gastroesophageal
  - NSCLC-squamous
  - Melanoma
  - MRCLS

MAGE-A4 target for both first-gen afami-cel and next-gen (ADP-A2M4CD8) programs

MRCLS: myxoid/round cell liposarcoma; NSCLC: non-small cell lung cancer
1. Mortality figures based on American Cancer Society 2022 (US) and Global Can (EU4/UK 2020)
2. MAGE-A4 expression based on ADAP samples and expression cut off criteria of ≥30% tumor cells at ≥2+ intensity *Synovial sarcoma and MRCLS MAGE-A4 expression based on 1,043 patient samples at November 20, 2020 data cut-off and expression of all other tumor types on 6,167 patients, 1,543 tumor samples at November 19, 2021 data cut-off.

Lete-cel

Clinical late-stage engineered TCR T-cell therapy targeting NY-ESO

NY-ESO
- NY-ESO-1 expressed in multiple solid tumor types: >80% expression in synovial sarcoma and Myxoid Round Cell Liposarcoma (MRCLS)[1,2,3]
- Letetresgene autoleucel (lete-cel) is an engineered TCR T-cell therapy targeting NY-ESO-1

Clinical Data
- Phase 1 data in synovial sarcoma (ASCO 2017): **ORR 61%** at target dose
- Data from planned interim analysis of pivotal IGNYTE-ESO: **18/45 (40%) ORR** by independent review

Corporate History
- Originally developed by Adaptimmune
- Further development under a collaboration and license agreement with GSK
- In 2023, Adaptimmune and GSK agreed terms regarding the return of NY-ESO program back to Adaptimmune

Recovery of lete-cel program now complete

Based on data cut off March 2nd 2023. Concordance of 85% between independent and investigator review
1. D’Angelo SP et al. J Clin Oncol. 2018;36(15_suppl):3005; 2. Endo M et al. Mod Pathol. 2015;28:587–595; 3 Gyurdieva A et al. Nature Communications 2022;13:5296

ADP-A2M4CD8 Next-Gen Cell Therapy Targeting MAGE-A4

ADP-A2M4CD8 monotherapy demonstrates strong efficacy | Data support continued development in SURPASS family of trials

35% response rate

~5 months median duration of response (mDOR) in heavily pre-treated patients across a broad range of solid tumors

50% response rate

in 26 patients with the focus indications of ovarian, urothelial, and head & neck cancers

75% response rate

in 12 patients who received three or fewer prior lines of therapy (“earlier line”) across focus indications

FUTURE

SURPASS-3 is a global Phase 2 trial enrolling people with platinum resistant **ovarian cancer**;
SURPASS Phase 1 trial now focused on **head & neck and urothelial cancers** in earlier line treatment setting

DISCLAIMER: This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument or to participate in any trading strategy. The summary may include “forward-looking statements” with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. This document has been furnished to you solely for your information.